MGC Pharmaceuticals Limited PDMR Notification

RNS Number : 6895I

MGC Pharmaceuticals Limited

28 March 2024

 

 

MGC Pharmaceuticals Ltd.

PDMR Notification

28 March 2024

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 240,000 unlisted options as approved at a meeting of shareholders on 18 March 2024. This notification is made in accordance the UK Market Abuse Regulations.

 

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Daniel Robinson
2	Reason for the notification
(a)	Position		Non-Executive Director
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		120,000	N/A
	Aggregated information
	AUD	0.00		120,000	N/A
(e)	Date of transaction		28 March 2024
(f)	Place of transaction		Outside a trading venue

 

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Layton Mills
2	Reason for the notification
(a)	Position		Non-Executive Director
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.42 on or before 28 March 2027.
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		120,000	N/A
	Aggregated information
	AUD	0.00		120,000	N/A
(e)	Date of transaction		28 March 2024
(f)	Place of transaction		Outside a trading venue

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd              Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DSHGCGDXLGDDGSI